Gilead Viread Adds Boxed Warning Regarding Hepatitis B Co-Infection
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients co-infected with HBV and HIV should be monitored for hepatic problems “for at least several months” if they discontinue Viread treatment. Labeling update also includes precautions about interactions with Abbott’s Kaletra and Bristol’s Reyataz.
You may also be interested in...
What Does A Typical Refuse-To-File Letter Look Like?
Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.
Pink Sheet Podcast: Dsuvia Warning Letter, Refuse-To-File Impact, CDER’s COVID Workload
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.
Pink Sheet Podcast: COVID-19 variants and vaccine trial dropouts, Aducanumab, User Fee Goal Changes
Pink Sheet reporters and editor discuss the latest coronavirus vaccine news, CMS’ effect on the future of aducanumab, as well as new assessment goals for PDUFA VII.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: